<DOC>
	<DOCNO>NCT02907710</DOCNO>
	<brief_summary>A total 300 patient pathologically confirm Locoregionally advance nasopharyngeal carcinoma enrol . Patients randomly divide two group , 150 patient group . One group treat Concurrent Chemoradiotherapy combine Endostar group treat Concurrent Chemoradiotherapy . The short term efficacy toxic side effect treatment evaluate . The 1-year , 3-year , 5-year overall survival progression-free survival patient analyze . The investigator data may provide alternative option treatment Locoregionally advance nasopharyngeal carcinoma high efficacy low toxicity .</brief_summary>
	<brief_title>Endostar Combined With Concurrent Chemoradiotherapy Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>This study multicenter , prospective , randomize control clinical trial . A set unified standard use , include clinical research program , inclusion criterion , exclusion criterion , chemoradiotherapy regimen evaluation criterion . Five medical center participate study 300 patient pathologically confirm Locoregionally advance nasopharyngeal carcinoma enrol . These patient stratify accord clinical stage participate center , randomly divide two group : concurrent chemoradiotherapy combine Endostar group ( IMRT 70-74Gy , Endostar 7.5mg / m2 , 3 cycle intravenous infusion , 2 cycle maintenance therapy radiotherapy ) concurrent chemoradiotherapy group ( IMRT 70-74Gy , DDP 100mg / m2 , intravenous infusion 2 hour , 2-3 cycle ) . After treatment , follow-up perform every 3 month . The treatment toxicity , local control rate , distant metastasis-free survival , overall survival , progression-free survival observe assessed .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1. patient either gender age 18 70 year old . 2. patient histologically confirm nonkeratinizing squamous cell nasopharyngeal carcinoma . 3. patient stage III/IVb UICC2010 stag . 4 . KPS ≥ 70 ( Appendix I ) 5. patient available MRI data nasopharynx measurable tumor lesion . 6. patient receive treatment enrollment . 7. patient expect survival long 6 month . 8. biochemical index : hemoglobin &gt; 120 g/L , WBC &gt; 4 x 109 /L , blood platelet ≥ 100 x 109 /L ; level indicator hepatic renal function 1.25 fold upper limit normal value . 9. informed content obtain every patient . 10. patient effective followup . 1. malignant tumor nasopharyngeal carcinoma , stage I nonmelanoma skin cancer , cervical carcinoma situ . 2. receive treatment enrollment . 3. pregnant lactate woman reproductive woman without contraception . 4. undergoing drug trial . 5. severe complication , include myocardial infarction , severe arrhythmia , severe cerebrovascular disease , ulcer disease , mental illness uncontrollable diabetes . 6. could follow regular interval . 7. treated tumor target drug . 8. could subject MRI examination . 9. could meet requirement prescribe dose . 10. hemorrhagic tendency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>endostar</keyword>
	<keyword>chemoradiotherapy</keyword>
</DOC>